Medical Oncology

MET+

Questions discussed in this category

How would you manage a patient with metastatic NSCLC and high-level MET amplification who achieved a near CR on tepotinib but is unable to tolerate dose-reduced tepotinib?

The patient did not receive immunotherapy initially due to delayed insurance authorization. His performance status is poor, and his main toxicity from...

1 Answer available

With the approval of capmatinib, how would you approach a newly diagnosed metastatic NSCLC with MET Exon 14 skipping mutation?

1 Answer available

Aside from MET exon 14 skip mutations, are there other targetable MET mutations or fusions that you would consider for TKI therapy?

Would you reserve TKI for after standard of care chemotherapy and immunotherapy or consider earlier line of treatment?

1 Answer available

What would be your approach in a patient with MET amplification and PDL-1 80% expression?

Do you use crizotinib for first-line therapy?

1 Answer available

Do you consider MET amplification in your first-line treatment decisions for patients with metastatic NSCLC?

1 Answer available

Papers discussed in this category

Cancer discovery, 2015-08

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

Annals of oncology : official journal of the European Society for Medical Oncology, 2018-10-01

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Nature, 2014-07-31

Comprehensive molecular profiling of lung adenocarcinoma.

Cancer discovery, 2015-08

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

The New England journal of medicine, 2014 Dec 04

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Lung Cancer, 2023 Apr

MET alterations in advanced non-small cell lung cancer.

Translational lung cancer research, 2025 Apr 17

Comprehensive management of MET tyrosine kinase inhibitor-induced peripheral edema in patients with -altered non-small-cell lung cancer: a narrative review.

The Lancet. Oncology, 2024 Oct

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial.

International journal of medical informatics, 2020 Aug 27

Prioritizing COVID-19 tests based on participatory surveillance and spatial scanning.

Medical Oncology

MET+

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology